• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes Fluorenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes

Introduction to Fmoc-S-benzyl-D-cysteine (CAS No. 252049-18-6)

Fmoc-S-benzyl-D-cysteine, with the chemical name N-(fluorenylmethyloxy-carbonyl)-S-benzyl-D-cysteine, is a specialized compound widely utilized in the field of peptide synthesis and bioconjugation. This compound, identified by its CAS number CAS No. 252049-18-6, plays a crucial role in the development of pharmaceutical intermediates and biomedical research. Its unique structure, combining the Fmoc (fluorenylmethyloxy-carbonyl) protecting group with a S-benzyl moiety on the D-cysteine backbone, makes it an invaluable tool for synthetic chemists and biochemists.

The Fmoc group is particularly significant in peptide chemistry as it provides an efficient and reversible protection strategy for the amino group during solid-phase peptide synthesis (SPPS). This protection allows for sequential addition of amino acids without interference from side reactions, ensuring high yields and purity of the final peptide product. The S-benzyl group, on the other hand, serves to protect the thiol group of cysteine, preventing unwanted oxidation and maintaining the integrity of the peptide backbone during synthetic processes.

In recent years, there has been a growing interest in the applications of Fmoc-S-benzyl-D-cysteine in various fields of biomedical research. One notable area is its use in the development of antibody-drug conjugates (ADCs). ADCs are a class of targeted cancer therapies that combine monoclonal antibodies with cytotoxic payloads to deliver drugs directly to tumor cells. The thiol group of cysteine is often utilized as a site for conjugation due to its high reactivity and stability under controlled conditions. Fmoc-S-benzyl-D-cysteine provides an excellent scaffold for this purpose, allowing for precise modification and conjugation of therapeutic agents.

The compound has also found applications in the synthesis of protease inhibitors, which are essential in treating various diseases such as HIV, hepatitis C, and cancer. Proteases are enzymes that play critical roles in many biological processes, including viral replication and tumor growth. By inhibiting specific proteases, these drugs can effectively disrupt pathogenic mechanisms. Fmoc-S-benzyl-D-cysteine serves as a key intermediate in the synthesis of these inhibitors, providing a versatile platform for drug design and development.

Moreover, Fmoc-S-benzyl-D-cysteine has been explored in the field of bioconjugation techniques, particularly in the development of fluorescent probes and imaging agents. These probes are used to visualize biological processes at the cellular and molecular levels, aiding in diagnostic and research applications. The combination of Fmoc protection and S-benzyl modification allows for precise functionalization, enabling researchers to tailor probes for specific biological targets.

The latest advancements in synthetic methodologies have further enhanced the utility of Fmoc-S-benzyl-D-cysteine. For instance, recent studies have demonstrated its application in catalytic asymmetric synthesis, where chiral compounds are synthesized with high enantioselectivity. This approach is crucial for producing pharmaceuticals with specific stereochemical configurations that exhibit optimal biological activity. The unique properties of Fmoc-S-benzyl-D-cysteine make it an ideal candidate for such transformations, offering chemists a powerful tool for constructing complex molecular architectures.

In conclusion, Fmoc-S-benzyl-D-cysteine (CAS No. 252049-18-6) is a multifaceted compound with significant implications in peptide synthesis, bioconjugation, and drug development. Its ability to serve as a versatile intermediate in various synthetic pathways underscores its importance in modern chemistry and biomedical research. As new methodologies continue to emerge, the applications of this compound are expected to expand further, driving innovation in pharmaceuticals and biotechnology.

• 29022-11-5(Fmoc-Gly-OH)
• 2900-27-8(Boc-Phg-OH)
• 3257-18-9(Z-Cys(Bzl)-OH)
• 2799-07-7(S-Trityl-L-cysteine)
• 131766-22-8(Fmoc-d-cys(tbu)-oh)
• 18942-46-6(Boc-Cys(Mob)-OH)
• 20887-95-0(Boc-L-cysteine)
• 21947-98-8((R)-2-((tert-Butoxycarbonyl)amino)-3-(tritylthio)propanoic acid)
• 1152-62-1(Z-Met-OH)
• 5068-28-0((R)-3-(Benzylthio)-2-((tert-butoxycarbonyl)amino)propanoic acid)